Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids

Abstract Background Patient-derived organoids (PDO) have been proposed as a novel in vitro method of drug screening for different types cancer. However, to date, extrahepatic biliary tract carcinoma (eBTC) PDOs not yet fully established. Methods We collected six samples gallbladder (GBC) and one sample cholangiocarcinoma (eCCA) from seven patients attempt establish eBTC screening. successfully established five GBC eCCA PDOs. Histological staining was used compare structural features between the original tissues cancer Whole exome sequencing (WES) performed analyze genetic profiles Drug screening, including gemcitabine, 5-fluorouracil, cisplatin, paclitaxel, infigratinib, ivosidenib, measured verified by clinical effects certain cases. Results Different exhibited diverse growth rates during culture. Hematoxylin eosin demonstrated that structures most retained adenocarcinoma. Immunohistological periodic acid-schiff revealed marker expression similar specimens. Genetic four specimens, well paired PDOs, were analyzed using whole sequencing. Three high degree similarity when compared except GBC2 PDO, which only had concordance 74% proportion single nucleotide polymorphisms coding sequence. In general, gemcitabine found be efficient treatment, it showed moderate or significant inhibitory impact on growth. confirmed extent three Conclusions Our study series contributed field Additional enhancements should explored improve rate preserve their immune microenvironment.